Alzchem Group Ag · XETR:ACT
Alzchem — Q3 2026 Earnings Presentation
31 slides from Alzchem's earnings presentation, Oct 29, 2026
Slide 1: Agile Science Pure Results
AGILE SCIENCE PURE RESULTS
Slide 2: Q3 2026 Analyst Presentation
Q3 ANDREAS NIEDERMAIER, CEO ANDREAS LÖSLER, CFO 2026 October 29, 2026
Slide 3: Disclaimer
DISCLAIMER CAUTIONARY NOTE REGARDING FORWARD - LOOKING STATEMENTS This presentation contains forward - looking statements about the business, financial condition and earnings performance of the Alzchem Group. These statements are based on assumptions and projections resting upon currently available
Slide 4: Agenda – Analyst Presentation Q3 2026
AGENDA – ANALYST PRESENTATION Q3 2026 I. Executive Summary II. Business and financial details III. Back - Up
Slide 5: Highlights
HIGHLIGHTS Alzchem is on expected growth level and confirms outlook Strong performance on group level : Major growth expansions are + 4% revenue growth progressing • Creatin capacity expansion in Germany + 8% EBITDA growth as scheduled • U.S. Nitroguanidin plant with cost and ✓ planning optimization
Slide 6: Agenda – Analyst Presentation Q3 2026
AGENDA – ANALYST PRESENTATION Q3 2026 I. Executive Summary II. Business and financial details III. Back - Up
Slide 7: Basics & Intermediates
BASICS & INTERMEDIATES The "Basics & Intermediates" segment comprises the production of basic and intermediate products that are marketed as independent products for example in agriculture, steel production and the automotive sector and as raw materials for the manufacture of specialty chemicals.
Slide 8: Basics & Intermediates Segment
BASICS & INTERMEDIATES SEGMENT (in M€) Sales and EBITDA development on expected level SALES - 21.2% SALES EBITDA SALES ANALYSIS 40.9 41.9 42.6 43.3 38.7 DELTA DELTA 35.6 36.7 34.1 33.5 Q3 01 - 09 - 9.9% Volume - 17.8% - 7.8% 121.6 Price - 3.6% - 1.9% 109.5 Currency + 0.2% - 0.2% Q3 Q4 Q1 Q2 Q3 Q4 Q1
Slide 9: Specialty Chemicals
SPECIALTY CHEMICALS The "Specialty Chemicals" segment produces and sells high - quality specialty chemical ingredients with strong growth perspectives.
Slide 10: Specialty Chemicals Segment
SPECIALTY CHEMICALS SEGMENT (in M€) Ingredients for Specialty Applications push Sales and EBITDA SALES +13.2% SALES EBITDA SALES ANALYSIS 100.1 105.3 109.0 98.5 DELTA DELTA 94.5 97.2 89.0 87.0 +11.1% Q3 01 - 09 80.4 Volume + 6.4% + 5.1% 312.7 Price + 5.9% + 6.9% 281.6 Currency + 0.9% - 1.0% Q3 Q4 Q1
Slide 11: Other & Holding
OTHER & HOLDING The "Other & Holding" segment offers infrastructure and energy supply services at our locations for the chemicals segments and for external customers.
Slide 12: Other & Holding Segment
OTHER & HOLDING SEGMENT (in M€) Regulated grid fees impact sales and result SALES SALES EBITDA COMMENTS +4.3% 7.7 8.1 7.5 7.6 7.3 • Sales broadly stable year - on- year with 7.1 7.0 6.7 6.6 - 0.4% slight decline driven by lower electricity grid fee pass - throughs 21.7 21.6 • Q3 revenue increased du
Slide 13: Financial Overview
FINANCIAL OVERVIEW Strong full - year performance with growth in all KPI Q3 Q3 2025 2026 Alzchem Group qoq % yoy % 2025 2026 1-9 1-9 SALES (in M€) 137.3 139.9 +1.9% 424.8 443.8 +4.5% EBITDA (in M€) 29.7 28.7 -3.5% 86.2 93.2 +8.1% EBITDA margin (in %) 21.7% 20.5% -1.1pp 20.3% 21.0% +0.7 pp Earnings p
Slide 14: Balance Sheet & Cashflow
BALANCE SHEET & CASHFLOW Balance sheet total shows the current growth CAPEX projects COMMENTS Balance sheet KPIs (T€) 31.12.2025 30.09.2026 Deviation • Increase in balance sheet tota l resulting from increased CAPEX Balance sheet total 617,679 673,711 56,032 9.1% Inventories 116,004 104,581 - 11,423
Slide 15: Outlook 2026
OUTLOOK 2026 (in M€) Ongoing growth in sales and EBITDA on expected level COMMENTS SALES growth EBITDA to approx. Outlook for 2026 confirmed 600 .0 M € Major assumptions are still valid growth +7% to approx. • Possible cost increases in energy and raw materials shall be passed 126 M€ through to cust
Slide 16: Financial Calendar
FINANCIAL CALENDAR Upcoming dates* OCT 29 2026 Quarterly Statement 3rd Quarter 2026 NOV 12- 13 2026 Jefferies Roadshow, New York, Boston NOV 23 - 24 2026 Deutsches Eigenkapitalforum , Frankfurt NOV 26 - 27 2026 Berenberg Roadshow, Stockholm DEC 1 2026 Berenberg European Conference, London DEC 10 202
Slide 17: Feedback
FEEDBACK We appreciate your feedback Were your expectations met? Are you missing any content? WE APPRECIATE YOUR FEEDBACK! Link QR - Code 17
Slide 18: Investor Relations
Investor Relations T +49 8621 86 - 2888 F +49 8621 86 - 502888 AGILE SCIENCE [email protected] PURE RESULTS www.alzchem.com
Slide 19: Agenda – Back-Up
AGENDA – ANALYST PRESENTATION Q3 2026 I. Executive Summary II. Business and financial details III. Back - Up
Slide 20: KPI Impact of Customer Grants
KPI IMPACT OF CUSTOMER GRANTS Timing and effects on balance sheet and P&L KPI EFFECTS KPI EFFECTS EST KEY EFFECTS 1 contract liablities other receiveables 2025/2026 2027 et seq. Cash / Assets ↑ Cash / Assets → Other receivables ↑ Other receivables ↓ receivables Equity → Equity ↑ liabilities Contract
Slide 21: Balance Sheet
BALANCE SHEET Alzchem Group ALZCHEM GROUP (IN T€) 31.12.2025 30.09.2026 Deviation ALZCHEM GROUP (IN T€) 31.12.2025 30.09.2026 Deviation Share capital 101,763 101,763 Intangible assets 3,530 4,018 489 13.8% RETAINED EARNINGS (+) / LOSS (-) 232,111 259,096 26,984 11.6% Tangible assets 276,980 353,611
Slide 22: Pension Accounting (IFRS)
PENSION ACCOUNTING (IFRS) Alzchem Group (M €) - 7.1% 88.2 82.0 +0.2 +2.7 - 2.2 - 7.0 75.9 - 6.1 IN FINANCIAL PENSION SERVICE NET INTEREST PENSION PENSION PENSION DEFERRED PENSION STATEMENT PROVISION COSTS COSTS PAYMENTS REMEASURE - PROVISION TAX ASSETS LIABILITY 31.12.2025 EBITDA MENTS 30.09.2026 30
Slide 23: Income Statement
INCOME STATEMENT Alzchem Group Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 ALZCHEM GROUP (IN T€) Deviation (Q3) 2025 2025 2025 2025 2026 2026 2026 2026 Revenue 144,680 142,879 137,266 137,290 148,653 155,250 139,882 2,616 2% Increase (+) / Decrease (-) in inventories of finished goods and work in progress 11,436 3,433
Slide 24: Income Statement
INCOME STATEMENT Alzchem Group Q3 Q3 YTD YTD ALZCHEM GROUP (IN T€) Deviation (QoQ) Deviation (YoY) 2025 2026 Sep.2025 Sep.2026 Revenue 137,266 139,882 2,616 1.9% 424,825 443,785 18,960 4.5% Increase (+) / Decrease (-) in inventories of finished goods and work in progress 624 -6,259 -6,882 <-1.000% 1
Slide 25: Cashflow Statement
CASHFLOW STATEMENT Alzchem Group Q3 Q3 1-9 1-9 CASHFLOW (IN M€) 2025 2026 2025 2026 Consolidated earnings before taxes 22,634 18,549 64,880 66,474 Depreciation on fixed and intangible assets 6,655 9,556 19,642 23,751 Decrease in pension provisions -612 -671 -1,986 -2,160 Loss (+) / Profit (-) from t
Slide 26: Segment Overview by Quarter
SEGMENT OVERVIEW BY QUARTER Alzchem Group SALES 2024 2025 2026 YTD Q3 2026 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Deviation PY (Q3) PY Actual Deviation PY (YOY) SALES T€ T€ T€ T€ T€ T€ T€ T€ T€ T€ T€ T€ T€ % T€ T€ T€ % Basics & Intermediates 49,299 41,848 40,927 41,929 42,638 35,605 43,309 33,539 36,66
Slide 27: Alzchem Group Locations
ALZCHEM GROUP LOCATIONS Production sites and sales companies BERLIN (GER) SUNDSVALL (SE) COVENTRY (UK) TROSTBERG (GER) SCHALCHEN (GER) HART a. d. ALZ (GER) WALDKRAIBURG (GER) © Alzchem Group AG / October 2026 SHANGHAI (CN) ATLANTA (USA) Production facilities in Germany (4) and Sweden (1) SALES COMPA
Slide 28: Verbund – Fully Integrated Business Model
“VERBUND” – FULLY INTEGRATED BUSINESS MODEL Vertically integrated production of chemical products based on the NCN chain Segment Specialty Chemicals BENEFITS OF “VERBUND” Segment Basics & Inter - • Full control of product quality and specifications mediates • Lower costs • Higher financial predictab
Slide 29: Our Products and Markets – Specialty Chemicals
OUR PRODUCTS AND MARKETS Successful with proven and new products in various industries MAIN PRODUCTS DESCRIPTION END - MARKETS A nutritional additive for poultry and pigs Feed additive Creapure ® , premium brand for creatine monohydrate as ingredient in sports & health nutrition Food supplements Die
Slide 30: Our Products and Markets – Basics & Intermediates
OUR PRODUCTS AND MARKETS Successful with proven and new products in various industries MAIN PRODUCTS DESCRIPTION END - MARKETS Calcium carbide - based mixtures for hot metal desulphurization Steel industry Fuel for airbags. key production of the intermediate product Automotive INTERMEDIATES Pharmace
Slide 31: Key Share Data
KEY SHARE DATA Share details as of October 27, 2026 SHAREHOLDER SHARES OUTSTANDING 10,176,335 four two na GmbH STRUCTURE 10.14% LAST CLOSING PRICE EUR 161.60 Staluna Trade a. s. 9.90% MARKET CAPITALIZATION EUR 1.644,5 m TICKER ACT Löw SE 6.39% WKN A2YNT3 ISIN DE000A2YNT30 © Alzchem Group AG / Octobe